This Weekly’s Hot Topics
- California Cancer PAC 2019 Legislative Update California News
- Contact your Congressional Representativesto co-sponsor the Clinical Treatment Act (HR913) National News
- CMS will not be issuing final NCD on CAR T-cell therapy for cancer. CMS News
MOASC & ANCO California Cancer PAC 2019 Legislative Update: Both houses held their Appropriations Suspense hearings last week. We are pleased to report that the bill that will require the Board of Pharmacy to create the Cancer Medication Advisory Task Force passed out of Committee on a unanimous vote. To read more click here and go to California News.
ANCO, MOASC, and ASCO call on all members to contact their Congressional Representatives to as ask them to become co-sponsors of the Clinical Treatment Act (HR913) that would guarantee overage of routine care costs of clinical trial participation for Medicaid enrollees with life-threatening conditions. To read more click here and go to National News.
National Coverage Analyses. Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers CMS will not be issuing a final National Coverage Determination on CAR T-cell therapy for cancer. The agency didn’t give any reason for the delay in finalizing the proposal that was released in February, but a decision is forthcoming. To read more click here and go to CMS News.
The Community Oncology Alliance is launching a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen abuse of patients with cancer is not lost in policy deliberations in Washington. For the past several months the California Oncology Weekly, under MOASC News, has been asking for oncology practices to please provide their “horror” stories of the obstruction to timely access to oncology care. To read more click here and go to Affiliate News.
To read the complete California Oncology Weekly Newsletter, click on the date below.